

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

- RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS

00 FEB 15 AM 9:01

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Powell, Goldstein, Frazer & Murphy LLP			
2. Address <input type="checkbox"/> Check if different than previously reported 1601 Pennsylvania Avenue, N.W., Suite 600, Washington, DC 20004			
3. Principal Place of Business (if different from line 2) City: N/A State/Zip (or Country)			
4. Contact Name Michael E. Fine	Telephone (202) 347-0666	E-mail (optional)	5. Senate ID # 31942-517
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research and Manufacturers of America (PhRMA)	6. House ID # 31255052		

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) OR Year End (July 1-December 31)


9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>160,000</u> <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ <small>Expenses (nearest \$20,000)</small></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature _____

Printed Name and Title _____



Registrant Name Powell, Goldstein, Frazer & Murphy LLP Client Name Pharmaceutical Research and Manufacturers of America

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

WTO enforcement actions on intellectual property rights; pharmaceutical industry goals for WTO Ministerial Conference

17. House(s) of Congress and Federal agencies contacted Check if None

Office of the U.S. Trade Representative
Patent and Trademark Office
Department of State
Department of the Treasury
U.S. Senate
U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Jeffrey Kushan		<input type="checkbox"/>
Andrew Shoyer		<input type="checkbox"/>
David Quam		<input checked="" type="checkbox"/>
Daniel Price		<input type="checkbox"/>
Alex Koff		<input checked="" type="checkbox"/>
Alysha Taylor		<input checked="" type="checkbox"/>
James Mendenhall		<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Daniel M. Price Date 2/14/2000

Printed Name and Title Daniel M. Price, Partner